Table 2.

Univariate analysis of factors associated with recurrence and survival

Factor	NR		DR		OS
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Age (years)	1.03 (1,1.05)	0.03	1.02 (0.99,1.04)	0.16	1.03 (0.98,1.09)	0.18
Gender (male)	1.08 (0.48,2.39)	0.86	1.50 (0.65,3.45)	0.34	1.76 (0.32,9.75)	0.52
Tumor size (cm)	1.22 (1.04,1.42)	0.01	1.26 (1.06,1.51)	0.01	1.48 (1.03,2.13)	0.03
Number of positive lymph nodes	1.06 (1.02,1.1)	0.001	1.06 (1.02,1.12)	0.008	1.02 (0.93,1.10)	0.70
LN positivity (yes/no)	2.29 (0.98,5.38)	0.06	2.83 (1.13,7.09)	0.03	1.90 (0.34,10.52)	0.46
Ct pre-op*1	1.6 (1.18,2.17)	0.003	1.19 (0.93,1.53)	0.17	2.00 (0.59,6.61)	0.26
CEA pre-op*2	2.13 (0.74,6.17)	0.16	7.57 (2.38,24.13)	0.001	n/a
Ct post-op*3	1.39 (1.13,1.70)	0.002	1.15 (0.9,1.46)	0.26	1.27 (0.80,2.01)	0.30
CEA post-op*4	1.17 (0.92,1.5)	0.21	1.71 (1.26,2.33)	0.001	1.85 (1.12,3.09)	0.02
Structural disease	2.93 (1.19,7.2)	0.09	1.89 (0.68,5.25)	0.22	1.38 (0.16,12.03)	0.77
Persistent biochemical disease	16.34 (2.29,116.72)	0.005	4.19 (0.99,17.59)	0.05	2.34 (0.26,21.12)	0.45

^*CEA and Ct levels were log-transformed.

¹n missing = 25

²n missing = 49

³n missing = 5

⁴n missing = 21